Body Mass Index, Weight Change and Death in an Older Hypertensive Population: The SHEP Study Grant W Somes Stephen B Kritchevsky Marco Pahor Ronald I Shorr.

Slides:



Advertisements
Similar presentations
Allison Dunning, M.S. Research Biostatistician
Advertisements

The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
Body mass index and waist circumference as predictors of mortality among older Singaporeans Authors: Angelique Chan, Chetna Malhotra, Rahul Malhotra, Truls.
SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
WHITE BLOOD CELL COUNT SECULAR TREND AND MORTALITY: THE BALTIMORE LONGITUDINAL STUDY OF AGING C.Ruggiero; E.J.Metter; A.Cherubini; M.Maggio; R.Sen; S.S.Najjar;
Meet the Author Webcast Public Health Reports Meet the Author Webcast Socioeconomic Status and Risk of Diabetes-Related Morality in the United States With.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.
Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
The Diabetes Prevention Program A U.S. Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
Body Weight and Mortality: New Population Based Evidences Body Weight and Mortality: New Population Based Evidences Dongfeng Gu, MD Dongfeng Gu, MD Fu.
HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)
OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.
The epidemiology of overweight and obesity Katherine M. Flegal, Ph.D. Centers for Disease Control and Prevention National Center for Health Statistics.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
Prevention Guidelines and the Risk of Nursing Home Admission Elmira Valiyeva, Ph.D., Rutgers Louise Russell, Ph.D., Rutgers Jane Miller, Ph.D., Rutgers.
A Randomized Trial of a Multivitamin in the Prevention of Cardiovascular Disease in Men: The Physicians’ Health Study II HD Sesso, WC Christen, V Bubes,
Does the weight history of patients with newly diagnosed type 2 diabetes influence the weight changes after diabetes diagnosis? Niels de Fine Olivarius.
Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.
Improving the Quality of Physical Health Checks
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
WHI CT Sample Size, Outcomes, Follow-up Women, aged Total CT = 68,133 Diet Modification (DM) Trial Primary Outcomes: Breast & Colorectal Cancer Secondary.
CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
Association between Systolic Blood Pressure and Congestive Heart Failure Complication among Hypertensive and Diabetic Hypertensive Patients Mrs. Sutheera.
Long-term mortality after acute stroke  Stroke is a leading cause of mortality: 6 million fatal events annually worldwide.  Mainly affects elderly, but.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute ALLHAT Major Outcomes in Moderately.
VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.
Short Sleep Duration is Associated with Hypertension only among Women: A Population-based Study Stranges S *, Dorn JM *, Cappuccio FP *, Donahue RP *,
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Identifying Persons in Need of Weight-loss Treatment: Evaluation of Potential Treatment Algorithms Caitlin Mason School of Physical and Health Education.
Retinopathy in Youth With Type 2 Diabetes Participating in the TODAY Clinical Trial Featured Article: TODAY Study Group* Diabetes Care Volume 36:
Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Dr. Rohit A, Dr Balu P S Public Health Specialist [ NCD] India
Vicky Copley, PHE Risk Factor Intelligence
C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
1 Body-Mass Index and Mortality in Korean Men and Women Sun Ha Jee, Ph.D., Jae Woong Sull, Ph.D., Jung yong Park, Ph.D., Sang-Yi Lee, M.D. From the Department.
The ACCORD Trial: Review of Design and Results
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
ACCORD Design and Baseline Characteristics
Title slide.
Blood Pressure and Age in Controlling Hypertension
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
by Sarah Steinmetz and Amber Brouillette
The Hypertension in the Very Elderly Trial (HYVET)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies 
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Presentation transcript:

Body Mass Index, Weight Change and Death in an Older Hypertensive Population: The SHEP Study Grant W Somes Stephen B Kritchevsky Marco Pahor Ronald I Shorr William B Applegate University of Tennessee Health Science Center, Memphis, TN

Background: Static Measures of Weight and Mortality In older populations, most studies show that low BMI is associated with increased mortality risk Fewer studies have shown that high BMI is associated with increased mortality risk The relationship with low BMI is attenuated in those with long-term weight stability, non-smokers, and those without weight related health conditions (Diehr et al., 1999; Calle et al., 1999).

Background: Dynamic Measures of Weight and Mortality On a population-level, there is a general tendency for adults to lose weight after age 60. The dynamics of this change may be intimately related to health status. In clinical settings, acute weight loss (>5%/year) is associated with increased mortality. Most previous studies in older populations have had only two weights, one of which is recalled from over a decade previously. There is little data on older populations, looking at the importance of short-term weight change and mortality risk

Study Questions: In older adults... What is the relationship between baseline BMI and mortality? Outside of a clinical setting is weight change associated with mortality? What are the simultaneous effects of static and dynamic measures of weight on mortality?

Systolic Hypertension in the Elderly Program (SHEP) Randomized clinical trial of 4736 (isolated systolic) hypertensives, age 60 and older, comparing drug treatment with placebo. Primary endpoint was stroke (fatal or non-fatal). Vital status known for nearly 100% of enrolled subjects. (n=455 deaths) Average duration of follow-up of 4.5 years.

Present Study Inclusion Criteria –> 3 weight values –>1 year follow-up beyond 3rd weight value Exclusion Criteria –Missing data related to BMI calculation at baseline (randomization visit). –Missing data related to covariates (eg. Gender, smoking, diabetes, prevalent CHD etc) 4485/4736 subjects were included 351 (7.83%) deaths

Methods BMI represents the BMI recorded at randomization visit (kg/m 2 ). Weight measured quarterly, and at other SHEP visits. Weight change is the average annualized weight change based on the regression of weight on time from baseline until one year before last measurement (death, loss to follow-up, or end of study). Other baseline variables are gender, age (divided at 70), current smoking status, and risks (previous heart attack, stroke or diabetes)

Analytic Strategy The primary outcome was all cause mortality. BMI and Weight Change were divided into quintiles Logistic regression was used to related mortality risk to weight change and baseline BMI compared to participants at lowest risk (23.6 to 28.0 BMI and -0.7 to 0.5 kg/year Weight Change) Covariates –Age –Gender –Baseline smoking status –“Risk” »Prevalent CVD »Diabetes

Distribution of Risk Factors and Mortality in SHEP (n= 4485 )

Distribution of time to event in SHEP

Baseline BMI and Mortality

Weight Change and Mortality

BMI, Weight Change and Death 1 year (n= 351)

BMI, Weight Change and Death 2 years (n=281)

Weight Change and Death, Baseline BMI > 31.1

Weight Change and Death, Baseline BMI < 23.6

Weight Change in BMI Groups BMI 31.1

Weight Change and Mortality by smoking status

Weight Change and Mortality by risk group

Weight Change and Cancer (n=135) or CVD (n=148) mortality

Baseline BMI and Cancer (n=135) or CVD (n=148) mortality

Multivariate Model

Discussion Weight loss of more than 0.7 kg/year was associated with high mortality risk--even in persons with high BMI. Weight gain of more than 0.5 kg/year was associated with high mortality risk--even in persons with low BMI. Findings consistent with 1-year and 2-year lag. Therefore observed relationship between weight change and mortality less likely to be ascribed to terminal illness. Our findings consistent across major causes of death.

Conclusions Limitations: –Setting: Clinical trial in Isolated Systolic Hypertension –Involuntary v. voluntary weight change Dynamic weight measures are a more important predictor of mortality than static weight measures. Weight stability regardless of BMI is associated low mortality in older adults.